Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

Similar articles for PubMed (Select 21544095)

1.

Lineage- and stage-restricted lentiviral vectors for the gene therapy of chronic granulomatous disease.

Barde I, Laurenti E, Verp S, Wiznerowicz M, Offner S, Viornery A, Galy A, Trumpp A, Trono D.

Gene Ther. 2011 Nov;18(11):1087-97. doi: 10.1038/gt.2011.65. Epub 2011 May 5.

PMID:
21544095
2.

CRISPR-mediated Genotypic and Phenotypic Correction of a Chronic Granulomatous Disease mutation in human iPS cells.

Flynn R, Grundmann A, Renz P, Haenseler W, James WS, Cowley SA, Moore MD.

Exp Hematol. 2015 Jun 19. pii: S0301-472X(15)00207-6. doi: 10.1016/j.exphem.2015.06.002. [Epub ahead of print]

PMID:
26101162
3.

Generation of X-CGD cells for vector evaluation from healthy donor CD34(+) HSCs by shRNA-mediated knock down of gp91(phox).

Brendel C, Kaufmann KB, Krattenmacher A, Pahujani S, Grez M.

Mol Ther Methods Clin Dev. 2014 Aug 27;1:14037. doi: 10.1038/mtm.2014.37. eCollection 2014.

4.

[A therapeutic approach towards chronic granulomatous disease].

Kawai T.

Nihon Rinsho Meneki Gakkai Kaishi. 2014;37(6):437-46. doi: 10.2177/jsci.37.437. Japanese.

5.

Gene therapy for chronic granulomatous disease: current status and future perspectives.

Kaufmann KB, Chiriaco M, Siler U, Finocchi A, Reichenbach J, Stein S, Grez M.

Curr Gene Ther. 2014;14(6):447-60.

PMID:
25245086
6.

Dual-regulated lentiviral vector for gene therapy of X-linked chronic granulomatosis.

Chiriaco M, Farinelli G, Capo V, Zonari E, Scaramuzza S, Di Matteo G, Sergi LS, Migliavacca M, Hernandez RJ, Bombelli F, Giorda E, Kajaste-Rudnitski A, Trono D, Grez M, Rossi P, Finocchi A, Naldini L, Gentner B, Aiuti A.

Mol Ther. 2014 Aug;22(8):1472-83. doi: 10.1038/mt.2014.87. Epub 2014 May 29.

PMID:
24869932
7.

Lentiviral vector-based gene therapy in Parkinson disease.

Richardson M.

Neurosurgery. 2014 Jun;74(6):N11-2. doi: 10.1227/01.neu.0000450231.24665.6d. No abstract available.

PMID:
24836099
8.

Preface: In 2013 gene therapy is a Nike; for 2014, just do it!

Anegon I.

Curr Gene Ther. 2014 Feb;14(1):1. No abstract available.

PMID:
24665838
9.

[Parkinson: the latest results of gene therapy].

Nau JY.

Rev Med Suisse. 2014 Jan 22;10(414):202-3. French. No abstract available.

PMID:
24624739
10.

Lentiviral vectors for the treatment of primary immunodeficiencies.

Farinelli G, Capo V, Scaramuzza S, Aiuti A.

J Inherit Metab Dis. 2014 Jul;37(4):525-33. doi: 10.1007/s10545-014-9690-y. Epub 2014 Mar 12. Review.

PMID:
24619149
11.

Gene correction of induced pluripotent stem cells derived from a murine model of X-linked chronic granulomatous disorder.

Mukherjee S, Thrasher AJ.

Methods Mol Biol. 2014;1114:427-40. doi: 10.1007/978-1-62703-761-7_28.

PMID:
24557920
12.

From bench to bedside: preclinical evaluation of a self-inactivating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous disease.

Stein S, Scholz S, Schwäble J, Sadat MA, Modlich U, Schultze-Strasser S, Diaz M, Chen-Wichmann L, Müller-Kuller U, Brendel C, Fronza R, Kaufmann KB, Naundorf S, Pech NK, Travers JB, Matute JD, Presson RG Jr, Sandusky GE, Kunkel H, Rudolf E, Dillmann A, von Kalle C, Kühlcke K, Baum C, Schambach A, Dinauer MC, Schmidt M, Grez M.

Hum Gene Ther Clin Dev. 2013 Jun;24(2):86-98. doi: 10.1089/humc.2013.019.

PMID:
23845071
13.

Hepatic gene therapy using lentiviral vectors: has safety been established?

Dismuke D, Samulski RJ.

Hepatology. 2013 Jul;58(1):13-4. doi: 10.1002/hep.26460. No abstract available.

PMID:
23695955
14.

Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapy.

Brendel C, Hänseler W, Wohlgensinger V, Bianchi M, Tokmak S, Chen-Wichmann L, Kuzmenko E, Cesarovic N, Nicholls F, Reichenbach J, Seger R, Grez M, Siler U.

Hum Gene Ther Methods. 2013 Jun;24(3):151-9. doi: 10.1089/hgtb.2012.157. Epub 2013 May 2.

15.

Alpharetroviral vector-mediated gene therapy for X-CGD: functional correction and lack of aberrant splicing.

Kaufmann KB, Brendel C, Suerth JD, Mueller-Kuller U, Chen-Wichmann L, Schwäble J, Pahujani S, Kunkel H, Schambach A, Baum C, Grez M.

Mol Ther. 2013 Mar;21(3):648-61. doi: 10.1038/mt.2012.249. Epub 2012 Dec 4.

16.

Gene therapy for primary immunodeficiencies: Part 2.

Aiuti A, Bacchetta R, Seger R, Villa A, Cavazzana-Calvo M.

Curr Opin Immunol. 2012 Oct;24(5):585-91. doi: 10.1016/j.coi.2012.07.012. Epub 2012 Aug 18. Review.

PMID:
22909900
17.

A simple and effective method to generate lentiviral vectors for ex vivo gene delivery to mature human peripheral blood lymphocytes.

Yang S, Karne NK, Goff SL, Black MA, Xu H, Bischof D, Cornetta K, Rosenberg SA, Morgan RA, Feldman SA.

Hum Gene Ther Methods. 2012 Apr;23(2):73-83. doi: 10.1089/hgtb.2011.199. Epub 2012 Apr 19.

18.

[Progress in improvement of lentiviral vectors' transcriptional read-through].

He J, Zhang J.

Sheng Wu Gong Cheng Xue Bao. 2011 Nov;27(11):1541-8. Review. Chinese.

PMID:
22393708
19.

Gene therapy for chronic granulomatous disease.

Kang EM, Malech HL.

Methods Enzymol. 2012;507:125-54. doi: 10.1016/B978-0-12-386509-0.00007-7.

PMID:
22365772
20.

Derivation and functional analysis of patient-specific induced pluripotent stem cells as an in vitro model of chronic granulomatous disease.

Jiang Y, Cowley SA, Siler U, Melguizo D, Tilgner K, Browne C, Dewilton A, Przyborski S, Saretzki G, James WS, Seger RA, Reichenbach J, Lako M, Armstrong L.

Stem Cells. 2012 Apr;30(4):599-611. doi: 10.1002/stem.1053.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk